Salarius Pharmaceuticals, INC. (DCOY) — DEF 14A Filings
All DEF 14A filings from Salarius Pharmaceuticals, INC.. Browse 4 Proxy Statement reports with AI-powered summaries and risk analysis.
DEF 14A Filings (4)
-
Salarius Pharma Sets Dec. 19 Annual Meeting, Board Backs All Proposals
— Nov 7, 2025 Risk: medium
Salarius Pharmaceuticals, Inc. (DCOY) is holding its 2025 Annual Meeting of Stockholders on December 19, 2025, to address three key proposals. Stockholders will -
Salarius Seeks Reverse Split, Capital Infusion to Bolster Nasdaq Listing
— May 27, 2025 Risk: high
Salarius Pharmaceuticals, Inc. (DCOY) filed a DEF 14A on May 27, 2025, outlining proposals for a Special Meeting of Stockholders on July 8, 2025. The primary ag -
Salarius Pharmaceuticals Files Preliminary Proxy Statement
— May 15, 2025 Risk: low
Salarius Pharmaceuticals, Inc. filed a preliminary proxy statement on May 15, 2025, for its annual meeting. The filing indicates no fee was required for this su -
Salarius Pharmaceuticals Announces Special Meeting for Reverse Stock Split
— Mar 26, 2024 Risk:
Salarius Pharmaceuticals, Inc. (DCOY) filed a Proxy Statement (DEF 14A) with the SEC on March 26, 2024. Salarius Pharmaceuticals will hold a Special Meeting of
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX